Amyloid hypothesis

Amyloid hypothesis. The amyloid hypothesis is a leading scientific framework proposing that the accumulation of amyloid beta peptides in the brain is the primary initiating event in the pathogenesis of Alzheimer's disease. This cascade is thought to trigger neurofibrillary tangles, neuroinflammation, and widespread neuronal death, ultimately leading to the clinical symptoms of dementia. First articulated in the early 1990s, it has dominated Alzheimer's disease research and drug development for decades, though it remains a subject of intense debate within the scientific community.

Overview

The central tenet posits that an imbalance between the production and clearance of amyloid beta, particularly the 42-amino acid form Aβ42, leads to its aggregation into soluble oligomers and insoluble amyloid plaques. These pathological assemblies are believed to be directly toxic to synapses and neurons, initiating a destructive cascade. The hypothesis is strongly supported by genetic studies of rare, early-onset familial Alzheimer's disease, where mutations in genes like APP, PSEN1, and PSEN2 invariably increase Aβ42 production. This framework has provided a clear, testable target for therapeutic intervention, guiding the work of numerous pharmaceutical companies and research institutions like the National Institute on Aging.

Development of the hypothesis

The hypothesis evolved from key pathological observations made by Alois Alzheimer and subsequent biochemical discoveries. In the 1980s, George Glenner and Colin Masters identified the core component of cerebral amyloid angiopathy and senile plaques as amyloid beta, derived from the amyloid precursor protein. The formal hypothesis was crystallized in a seminal 1992 paper by John Hardy and Gerald Higgins, often termed the "amyloid cascade hypothesis." Further genetic evidence from studies of Down syndrome and families with mutations in the APP gene on chromosome 21 solidified the model. Landmark work by Dennis Selkoe and others at Harvard Medical School detailed the proteolytic processing of APP by secretases like BACE1.

Evidence supporting the hypothesis

The most compelling evidence comes from autosomal dominant forms of Alzheimer's disease linked to mutations in APP, PSEN1, and PSEN2, all of which alter amyloid beta metabolism. The development of transgenic mouse models, such as the PDAPP mouse created by researchers at Johns Hopkins University, recapitulated amyloid plaque deposition and some cognitive deficits. Biomarker studies, including Pittsburgh compound B PET imaging and cerebrospinal fluid assays, show amyloid beta accumulation precedes clinical symptoms by years. Furthermore, the DIAN study and other preclinical cohorts have tracked this pathological sequence in living individuals.

Challenges and controversies

A major critique is the repeated failure of anti-amyloid therapies, such as semagacestat from Eli Lilly or verubecestat from Merck & Co., to improve cognition in large clinical trials. The dissociation between amyloid plaque burden and the severity of dementia in some individuals challenges its primacy. Notable scientists like Robert D. Terry and Peter Davies have long emphasized the importance of neurofibrillary tangles containing tau protein. The controversial approval of aducanumab by the U.S. Food and Drug Administration, despite equivocal clinical benefits, intensified debate about the hypothesis's validity.

Therapeutic implications

The hypothesis has driven a massive drug development pipeline focused on reducing amyloid beta production, preventing its aggregation, or enhancing its clearance. This includes gamma-secretase inhibitors, BACE inhibitors, and immunotherapies like solanezumab, crenezumab, and lecanemab. The latter, developed by Eisai and Biogen, received accelerated approval from the FDA based on amyloid clearance. Current strategies, exemplified by the A4 study, emphasize intervention in the preclinical stage of Alzheimer's disease, often using amyloid PET for participant selection.

Alternative hypotheses

Other pathogenic mechanisms have been proposed, often as complementary or primary drivers. The tau hypothesis focuses on hyperphosphorylated tau and neurofibrillary tangles as the main cause of neurodegeneration. The inflammatory hypothesis, supported by work from Joseph Rogers on microglia, implicates chronic neuroinflammation as a key contributor. The cholinergic hypothesis, which led to the development of drugs like donepezil, posits a primary deficit in the neurotransmitter acetylcholine. Other lines of inquiry explore the roles of apolipoprotein E, mitochondrial dysfunction, and infectious agents like Herpes simplex virus. Category:Medical hypotheses Category:Neuroscience Category:Alzheimer's disease